|1.||Burke, Steven K: 10 articles (12/2008 - 07/2002)|
|2.||Ketteler, Markus: 7 articles (06/2015 - 11/2005)|
|3.||Nagano, Nobuo: 7 articles (03/2006 - 06/2003)|
|4.||Chertow, Glenn M: 5 articles (05/2014 - 07/2002)|
|5.||Slatopolsky, Eduardo: 5 articles (12/2013 - 09/2002)|
|6.||Cozzolino, Mario: 5 articles (03/2012 - 09/2002)|
|7.||Fukushima, Naoshi: 5 articles (06/2004 - 06/2003)|
|8.||Maizel, Julien: 4 articles (11/2014 - 11/2005)|
|9.||Massy, Ziad A: 4 articles (11/2014 - 11/2005)|
|10.||Keith, Michael S: 4 articles (10/2014 - 12/2011)|
11/01/2014 - "Sevelamer is a phosphate binder that allows a better control of hyperphosphatemia, like other phosphate binder agents, but it has additional pleiotropic effects such as correcting certain abnormalities of lipid metabolism and clearance of several uremic toxins. "
07/01/2008 - "Sevelamer is a phosphate-binder used effectively for the treatment of hyperphosphatemia in patients treated with dialysis. "
12/01/2007 - "Sevelamer appears useful for the treatment of hyperphosphatemia in these patients. "
10/01/2008 - "In addition, the efficacy of sevelamer as a monotherapy in lowering phosphate to target levels in severe hyperphosphatemia remains debatable. "
06/01/2015 - "In this study, we attempted to create a peptide specific antibody that produced outcomes similar to those of the human pharmaceutical, sevelamer HCl, used in the treatment of hyperphosphatemia (a sequela of chronic renal disease). "
|2.||Hypercalcemia (Milk Alkali Syndrome)
04/01/2006 - "The marked decrease in lipid levels and lower rate of hypercalcemia may augment the long-term benefit of sevelamer."
01/01/2015 - "This meta-analysis suggests that sevelamer benefits dialysis patients in terms of CACS, ACS and hypercalcemia."
05/01/2014 - "However, sevelamer hydrochloride seems to be superior among all with lowering incidence of hypercalcemia. "
01/01/2014 - "Sevelamer hydrochloride has been introduced as an efficient medication for phosphate control, with a lower risk of hypercalcemia and parathyroid suppression. "
06/01/2004 - "The incidence of hypercalcemia for sevelamer was not different from the incidence of hypercalcemia during the washout period. "
|3.||Chronic Kidney Failure (Chronic Renal Failure)
12/01/2013 - "Endothelial effects of sevelamer may contribute mechanistically to the improved survival observed in some studies of CKD and ESRD patients."
05/01/2013 - "Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study."
09/01/2005 - "The safety and efficacy of sevelamer hydrochloride in binding phosphate in patients with end-stage renal disease and its ability to attenuate the progression of cardiac calcification have been well documented but not the longer-term health and economic implications. "
01/01/2011 - "Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study."
01/01/2004 - "The aim of our study is to investigate retrospectively the gastrointestinal tolerance of sevelamer, their efficacy as phosphate binder and other parameters in a group of 89 patients with chronic renal failure in predialysis. "
|4.||Kidney Diseases (Kidney Disease)
01/01/2013 - "Additional studies are needed to evaluate the potential effects of sevelamer treatment on nutritional status in chronic kidney disease (CKD) patients with elevated ET."
05/01/2012 - "From the results of this multicentric, comparative, randomized clinical study on sevelamer carbonate we can recommend that sevelamer carbonate may be used as a phosphate binder in Indian chronic kidney disease patients."
04/01/2009 - "The aim of study was the estimation of efficacy and safety of sevelamer treatment in children with chronic kidney disease with resistant hyperphsphatemia. "
07/01/2008 - "This study investigated the ability of sevelamer carbonate to control serum phosphorous in hyperphosphatemic patients who had chronic kidney disease and were not on dialysis. "
10/01/2004 - "We will review the published series, with special reference to the Sevelamer Treat to Goal trial and also discuss the new Kidney Disease Outcome Quality Initiative (K-DOQI) guidelines on the use of phosphate binders in chronic kidney disease."
|5.||Renal Insufficiency (Renal Failure)
01/01/2010 - "Update and critical appraisal of sevelamer in the management of chronic renal failure."
01/01/2010 - "The aim of this study was to evaluate the ET-binding capacity of sevelamer carbonate in an animal model of renal failure. "
03/01/2012 - "Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective."
01/01/2010 - "In addition, preclinical models of renal failure and preliminary clinical data on hemodialysis patients suggest a potential benefit for bone with sevelamer. "
11/01/2010 - "Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V)."
|3.||Calcium Carbonate (Limestone)
|4.||calcium acetate (Phoslo)
|8.||lanthanum carbonate (Fosrenol)
|1.||Renal Dialysis (Hemodialysis)